
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
An age-dependent increase in ceramide levels in the lungs of mice with cystic fibrosis causes many of the symptoms of the disease, which can be reversed by an inhibitor that normalizes ceramide levels, according to research published online March 30 in Nature Medicine.






